Immunogen (IMGN) Posts Q4 Loss of 71c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results
July 31, 2015 6:30 AM EDTCompany Provides Corporate Update and Fiscal Year 2016 Financial Guidance
Conference Call Today at 8:00 am ET
ImmunoGens wholly owned mirvetuximab soravtansine demonstrates notable single-agent activity in early clinical testing for platinum-resistant ovarian cancer; Company plans to initiate later-stage testing this year. Events expected with other ImmunoGen product candidates in 2H2015 include initiation of clinical assessment of IMGN529 in combination with rituximab (Rituxan®) and submission of the IMGN779 IND. Events expected among partner compounds in the next 12 months include presentation of new clinical data, start of... More